N-(2-Bromoethyl)-4,4-dimethyl-1,2,3,4-tetrahydroquinoline | 900865-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(2-Bromoethyl)-4,4-dimethyl-1,2,3,4-tetrahydroquinoline
• 英文别名: 1-(2-bromoethyl)-4,4-dimethyl-2,3-dihydroquinoline
• CAS: 900865-01-2
• 化学式: C₁₃H₁₈BrN
• 分子量: 268.197
• InChiKey: LADMHJQKWKEBHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(2-Bromoethyl)-4,4-dimethyl-1,2,3,4-tetrahydroquinoline 、 苯甲酰氯 在 四氯化钛 作用下， 以 1,2-二氯乙烷 为溶剂， 以71%的产率得到N-(2-Bromoethyl)-4,4-dimethyl-6-benzoyl-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

  摘要：

  Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic beta-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPAR alpha, PPAR gamma and PPAR beta/(delta). We were interested in designing novel PPAR gamma selective agonists and/or dual PPAR alpha/gamma agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.067
• 作为产物：
  描述：

  在 硼烷四氢呋喃络合物 作用下， 以 甲苯 为溶剂， 生成 N-(2-Bromoethyl)-4,4-dimethyl-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

  摘要：

  Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic beta-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPAR alpha, PPAR gamma and PPAR beta/(delta). We were interested in designing novel PPAR gamma selective agonists and/or dual PPAR alpha/gamma agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.067

文献信息

• Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them
  申请人：Parmenon Cicile

  公开号：US20090124656A1

  公开（公告）日：2009-05-14

  Compounds of formula (I): wherein: R 1 , R 2 , R 3 , R 4 and X are as defined in the description, A represents an alkylene chain as defined in the description, B represents an alkyl or alkenyl group substituted by a group or R 7 , or B represents a group or R 7 . Medicinal products containing the same which are useful as hypoglycaemic and hypolipaemic agents.

  式(I)的化合物：其中：R1、R2、R3、R4和X如描述中所定义，A表示如描述中所定义的烷基链，B表示被基团或R7取代的烷基或烯基，或者B表示基团或R7。含有上述化合物的药物，可用作降血糖和降脂药物。
• NOUVEAUX DERIVES D'OXIMES HETEROCYCLIQUES, LEURS PROCEDE DE PREPARATION , LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT ET LEURS UTILISATION POUR LE TRAITEMENT DE L'OBESITE
  申请人：Les Laboratoires Servier

  公开号：EP1844015A2

  公开（公告）日：2007-10-17
• [EN] NOVEL HETEROCYCLIC OXIME DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME<br/>[FR] NOUVEAUX DERIVES D'OXIMES HETEROCYCLIQUES, LEURPROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
  申请人：SERVIER LAB

  公开号：WO2006079719A2

  公开（公告）日：2006-08-03

  [EN] The invention concerns compounds of formula (I), wherein: R¹, R², R³, R⁴ and X are such as defined in the description; A represents an alkylene chain such as defined in the description; B represents an alkyl or alkenyl group substituted by a group (a) or R⁷, or B represents a group (b) or R⁷. The invention is applicable to preparation of medicines.
  [FR] Composés de formule (I) : NOR Me Me dans laquelle : > R1, R2, R3, R4 et X sont tels que définis dans la description, > A représente une chaîne alkylène telle que définie dans la description, > B représente un groupement alkyle ou alkényle substitués par un groupement K RD ou R7, ou B représente un groupement ou R7. R° R0 Médicaments